CLINICAL TRIALS PROFILE FOR ETANERCEPT

Biosimilar Clinical Trials for etanercept

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01891864 ↗	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel	Completed	Hexal AG	Phase 3	2013-06-01	The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
NCT01891864 ↗	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel	Completed	Sandoz	Phase 3	2013-06-01	The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
NCT03273088 ↗	Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects	Completed	AryoGen Pharmed Co.	Phase 1	2016-12-04	This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate Altebrel relative to etanercept reference product (Enbrel®) and evaluate safety and tolerability of Altebrel, in a crossover fashion in healthy male volunteers after administration of a single dose (25 mg) of etanercept. The primary objective of this study is to demonstrate that the PK of Altebrel is similar to its originator, Enbrel®, as assessed by the area under the serum concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and the Cmax. The secondary objectives of the study are: To further compare the PK of Altebrel and Enbrel®. To assess the safety of Altebrel.

All Clinical Trials for etanercept

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000433 ↗	Blocking Tumor Necrosis Factor in Ankylosing Spondylitis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1999-10-01	The Division of Rheumatology at University of California San Francisco is conducting a research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin. It blocks the action of tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid arthritis, and other inflammatory conditions. We will randomly assign patients to receive either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.
NCT00001862 ↗	TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis	Completed	National Eye Institute (NEI)	Phase 2	1999-02-01	This study will investigate the safety and effectiveness of the drug TNFR:Fc to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis. In other studies, TNFR:Fc significantly reduced joint pain and swelling in adult patients with rheumatoid arthritis, and the Food and Drug Administration has approved the drug for that use. Because medicines for arthritis often help patients with eye inflammation, this study will examine whether TNFR:Fc can help patients with uveitis. Patients with uveitis who are not responding well to standard treatment, such as steroids, and patients who have side effects from other medicines used to treat their uveitis or have refused treatment because of possible side effects may be eligible for this study. Candidates will be screened with a medical history, physical examination, and eye examination. The eye exam includes a check of vision and eye pressure, examination of the back of the eye (retina), and front of the eye, including measurements of protein and inflammation. Candidates will also undergo fluorescein angiography-a procedure in which photographs are taken of the retina to see if there is any leakage in the eye's blood vessels. A blood test and joint evaluation will also be done. Study participants will be given a shot of TNFR:Fc twice a week for up to 12 months and may continue other medicines they may be taking, such as prednisone or methotrexate. They will have follow-up examinations at week two and months one, two, three and four. Those who wish to continue treatment after the fourth month can receive the drug for another eight months and will have follow-up exams at months six, nine and 12, and one month after treatment ends. Each follow-up visit will include a repeat of the screening exams and an evaluation of side effects or discomfort from the medicine.
NCT00001901 ↗	Etanercept to Treat Wegener's Granulomatosis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1999-02-01	This study will examine the use of etanercept (also called Enbrel or TNFR:Fc) in patients with Wegener's granulomatosis, a type of vasculitis (blood vessel inflammation). Wegener's granulomatosis may affect many parts of the body, including the brain, nerves, eyes, sinuses, lungs, kidneys, intestinal tract, skin, joints, heart, and other sites. Generally, the greater the disease involvement, the more life-threatening it is. Standard treatment is a combination of prednisone and a cytotoxic agent-usually cyclophosphamide or methotrexate. However, many patients treated with this regimen have a disease relapse, and others cannot take these drugs because of severe side effects. This study will evaluate etanercept's safety and effectiveness, and particularly its value in reducing the need for prednisone and preventing disease relapse. The Food and Drug Administration has approved etanercept for treating rheumatoid arthritis, another inflammatory disease. The drug works by blocking the activity of TNF-a protein made by white blood cells that is involved in the inflammatory process. Since prednisone also affects inflammatory proteins and lowers TNF production, the use of etanercept may reduce the need for prednisone in patients with Wegener's granulomatosis, and thus the risk of its side effects. Patients between 10 and 70 years of age with Wegener's granulomatosis who have never taken prednisone, methotrexate or cyclophosphamide, or have taken these drugs for less than 3 weeks may be eligible for this study. Participants will have a medical history review and physical examination, including laboratory studies. If medically indicated, X-rays, consultations and biopsies (surgical removal of a small tissue sample) of affected organs will also be done. All patients will begin treatment with prednisone, methotrexate and etanercept. Those who improve on this regimen will stop prednisone gradually over 3 months. Those who achieve disease remission at the end of another 3 months will be randomly assigned to either continue taking etanercept and methotrexate for another 12 months or to stop etanercept and continue only methotrexate for the next 12 months (after which methotrexate will gradually be stopped). Patients who are not in remission by the 6-month point will continue taking etanercept until they go into remission, when they will be assigned to stop or not stop etanercept, as described above. Patients who do not achieve remission within 12 months of beginning treatment will be taken off the study. Patients who have a disease relapse while on the study will likely be switched to treatment with prednisone and either methotrexate or cyclophosphamide. Patients randomized to stop etanercept and who have a relapse within a year of stopping the drug may be offered re-treatment on this protocol, but with continuing etanercept for a full year after remission. Patients will be evaluated in the outpatient clinic every 2 to 4 weeks for the first 4 months and every 1 to 3 months after that. Patients whose disease is in remission and who stop all medications will be followed every 3 to 6 months for 2 years. Follow-up evaluations include a physical examination, blood draws and, if medically indicated, X-rays. The total study duration is 60 to 70 months.

Clinical Trial Conditions for etanercept

Condition Name

Condition Name for etanercept
Intervention	Trials
Rheumatoid Arthritis	100
Psoriasis	61
Ankylosing Spondylitis	27

Condition MeSH

Condition MeSH for etanercept
Intervention	Trials
Arthritis	149
Arthritis, Rheumatoid	123
Psoriasis	86

Clinical Trial Locations for etanercept

Trials by Country

Trials by Country for etanercept
Location	Trials
Canada	156
Spain	98
Japan	76
United Kingdom	73
Germany	65

Trials by US State

Trials by US State for etanercept
Location	Trials
California	66
New York	56
Florida	53
Texas	51
Pennsylvania	42

Clinical Trial Progress for etanercept

Clinical Trial Phase

Clinical Trial Phase for etanercept
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for etanercept
Clinical Trial Phase	Trials
Completed	262
Unknown status	33
Recruiting	31

Clinical Trial Sponsors for etanercept

Sponsor Name

Sponsor Name for etanercept
Sponsor	Trials
Amgen	70
Wyeth is now a wholly owned subsidiary of Pfizer	51
Pfizer	46

Sponsor Type

Sponsor Type for etanercept
Sponsor	Trials
Other	338
Industry	289
NIH	42

Etanercept Clinical Trials Update and Market Projection (2026–2035): Pipeline, Patent/Exclusivity Risks, and Growth Outlook

Last updated: July 29, 2026

Etanercept remains a high-volume TNF inhibitor with multiple biosimilars in the US and EU. The near-term market picture is dominated by biosimilar competition, expanding non-inflammatory indications, and incremental line extensions (biomarkers, combination regimens, and comparative studies) rather than a single late-stage breakthrough.

What is etanercept’s current clinical development status and trial pipeline?

Featured snippet: Etanercept’s active development focus is mostly comparative, translational, or label-expansion work rather than large new global phase 3 programs, reflecting biosimilar maturity and competitive pressure across TNF classes.

Which trials are most relevant right now (by intent)?

Most currently visible clinical activity clusters into four buckets:

1. Label expansion and sequencing

   • Studies in inflammatory diseases where TNF inhibition is used long-term, often comparing etanercept positioning with other systemic options.
   • Trials frequently assess outcomes in biologic-naïve versus biologic-experienced patients.

2. Comparative effectiveness and switching

   • Real-world and pragmatic trials that evaluate outcomes after switching within the TNF inhibitor class or between biologics.
   • Key endpoints include persistence, drug survival, disease activity scores, and safety.

3. Combination regimens

   • Etanercept combined with conventional DMARDs or targeted agents in subpopulations (safety, immunogenicity, and efficacy).
   • Trial design often aims to clarify additive benefit rather than show superiority to standard TNF monotherapy.

4. Safety, immunogenicity, and infection-risk management

   • Monitoring protocols for serious infection, vaccination responses, and risk stratification.
   • Biomarker-driven work aims to identify responders and reduce unnecessary exposure.

Trial design trends that affect commercial translation

• Use of disease activity score endpoints (PsA, RA, AS) to support positioning in payor formularies and treatment guidelines.
• Head-to-head comparisons are limited; most programs are non-inferiority, observational, or mechanistic.
• Subgroup trials are more common than broad new phase 3 launches, lowering the chance of a new “blockbuster-style” indication.

How big is the etanercept market now, and what is the revenue split by geography?

Featured snippet: Etanercept’s global market is sizable but shrinking in unit economics due to biosimilar erosion and pricing pressure; North America and Western Europe drive a large share, with Asia showing mixed growth depending on access and local tender dynamics.

Market drivers

• Biosimilar substitution for chronic TNF use
• Health system protocols that favor lower net-price biologics
• Guideline adherence in RA, PsA, AS, and juvenile idiopathic arthritis
• Treat-to-target strategies increasing biologic continuity and persistence
• Infection-risk monitoring shaping adherence and persistence

Market inhibitors

• Switching and drug survival favoring best-performing molecules in payer negotiations
• Therapeutic class saturation as IL-17, IL-23, JAK inhibitors, and other biologics compete in overlapping indications
• Patent-to-biosimilar economics: even when efficacy is similar, net price differences drive volume

Which biosimilars are competing with etanercept, and how does that change pricing?

Featured snippet: Competitive pricing compresses etanercept net revenue, with substitution reducing the addressable market for originator sales.

US competition and formulary dynamics

• Multiple etanercept biosimilars are listed and used clinically in RA, PsA, AS, and juvenile indications.
• Formularies increasingly use step therapy and non-medical switching policies, especially in Medicare Advantage and managed commercial plans.

EU competition pattern

• EU biosimilar adoption differs by country procurement and tendering practices.
• Tender winners can hold market share even if multiple products are clinically equivalent.

Commercial impact mechanism

• Net price decline drives revenue compression even if total patient numbers remain stable.
• Higher persistence for specific biosimilars can partially offset unit price erosion, creating “winner takes switching” dynamics.

When does etanercept lose exclusivity, and what is the patent landscape risk?

Featured snippet: Etanercept’s originator exclusivity has largely expired; current revenue protection depends on remaining formulation, method-of-use, manufacturing process, and pediatric/label-specific patents, which are less likely to block biosimilar competition at scale.

Originator exclusivity and key practical implications

• The originator market protection phase is over.
• Remaining value focuses on:
  • Lifecycle patents that may block specific formulations or specific sub-indications
  • Data exclusivity or regulatory exclusivity that can delay approval for certain biosimilar contexts
  • Litigation-driven settlements in specific jurisdictions and time windows

What patents protect etanercept today (how to read the risk)?

In practice, the “patent estate” risk for etanercept is fragmented:

• Drug product formulation patents: may be narrow (specific buffers, stabilizers, or container closure systems).
• Manufacturing process patents: can be more important for blocking a biosimilar if claims are broad enough and infringement is plausible.
• Method-of-use claims: often limited by differences in dosing, patient selection, or endpoints.
• Packaging/device patents: can block a specific device or presentation.

Litigation and settlement pattern

For many mature biologics, litigation is:

• earlier in the biosimilar entry cycle
• less likely to materially affect broad commercial availability once multiple biosimilars launch

What is the Orange Book status of etanercept, and how does it affect generic entry risk?

Featured snippet: Etanercept is a biologic and is typically tracked in biologics regulatory frameworks rather than through the Orange Book listing model used for small-molecule drugs; biosimilar and interchangeability status determines entry risk more than “generic” Orange Book paragraph IV style challenges.

How exclusivity is handled for biologics

• Biosimilar entry is governed by BLA pathway standards and exclusivity rules under biologics law.
• The operational risk is not “paragraph IV generic triggers” as with ANDA small molecules; it is whether biosimilar applicants can rely on prior reference data and whether patents listed for the reference product block specific versions or methods.

What formulations and delivery systems are protected, and where are infringement risks?

Featured snippet: For etanercept, formulation and presentation patents tend to be the most relevant residual IP, though many are narrow and do not stop clinical use of approved biosimilars with different manufacturing lots or container systems.

Presentation-specific issues

• Prefilled syringe vs autoinjector vs vials can involve distinct packaging, device interface, and labeling.
• Residual IP sometimes maps to:
  • stabilizer systems
  • pH/buffer composition targets
  • container closure compatibility
  • device delivery mechanics

How this changes biosimilar differentiation

• Competitors choose presentations that align with their regulatory pathway and manufacturing constraints.
• Infringement risk shifts to the subset of patents that claim device or formulation composition with specificity that can be designed around.

What patent litigation affects etanercept biosimilars and ongoing commercialization?

Featured snippet: Litigation is typically concentrated around initial biosimilar approvals and specific listed patents; late-stage impacts on broad market access are uncommon once multiple biosimilars are established.

What to look for in disputes

• Whether the suit addresses:
  • product formulation claims
  • manufacturing process claims
  • method-of-use claims tied to a clinical regimen or population
• Whether settlements produce:
  • launch “carve-outs”
  • delayed approval windows for certain presentations
  • specific indemnities or non-exclusive licenses

Practical business effect

Even if a particular patent blocks one applicant, multiple other biosimilar sponsors can still enter through design-arounds or independent non-infringing approaches.

How strong is the patent estate for etanercept versus other TNF inhibitors?

Featured snippet: The etanercept originator patent estate is no longer the primary determinant of market access. Compared with newer TNF inhibitors (or competitors with later-expiring IP), the incremental protection tends to be thinner and more fragmented.

Competitive comparison framework (business relevant)

• Residual IP breadth
  • Newer competitors often have broader method-of-use or biologic engineering claims still within term.
• Lifecycle strategy effectiveness
  • If lifecycle patents are narrow, biosimilar sponsors can often design around without losing approval speed.
• Regulatory and patent linkage coverage
  • Where remaining patents map to multiple presentations, they can slow entry. For mature etanercept, the linkage is typically manageable.

What is the etanercept biosimilar market entry scenario under different policy regimes?

Featured snippet: The market is most sensitive to substitution policy, tendering, and interchangeability frameworks rather than to small-molecule-style generic launch timing.

Scenario A: Strong formulary preference for lowest net price

• Continued rapid substitution.
• Originator share continues to decline.
• Forecast emphasizes net price compression more than volume growth.

Scenario B: Clinical switching resistance and physician-led continuity

• Biosimilar adoption continues but slower.
• Brand persistence lifts revenue versus pure price-cut scenarios.

Scenario C: Tender consolidation and winner-takes-market

• One or two biosimilar SKUs dominate procurement.
• Revenue shifts across biosimilar sponsors, not away from the class.

Revenue projections: what is the market outlook for etanercept through 2035?

Featured snippet: The core expectation for etanercept is modest volume stability with sustained net-price erosion from biosimilars, offset by potential partial recoveries from new sub-indication uptake and retention improvements.

Projection logic (how to model it)

1. Patient base stability
   • TNF inhibitors remain standard-of-care in RA and several inflammatory diseases.
2. Share shifting from originator to biosimilars
   • Net prices fall as discounts expand.
3. Class competition
   • JAK inhibitors and IL-17/IL-23 therapies can cannibalize subsets.
4. Persistence effects
   • Better tolerability or payer design can increase drug survival in chosen products.

Baseline financial direction (directionally)

• Originator revenue: declining, with potential stabilization where originator-only formulations or contracts remain.
• Biosimilar revenues: growing on volume, but value depends on tender dynamics and competitive intensity.
• Overall class revenue: may flatten; total biologic spend in RA and PsA can keep rising, but allocation shifts toward winners.

Key strategic implications for R&D, licensing, and investment

If you are assessing new entrants or line extension opportunities

• Winning strategies for etanercept-focused programs likely require:
  • differentiated endpoints (persistence, PROs, infection-risk reduction)
  • payer-relevant adherence improvements
  • manufacturing cost advantages and presentation strategy
• Late phase “new indication” bets are higher risk because biosimilar availability dampens ROI and reduces time windows.

If you are considering licensing or partnership

• The highest-value deals are usually:
  • non-exclusive grants tied to distribution/presentation
  • manufacturing know-how where process claims matter
  • regional exclusivity where procurement rules allow premium pricing

If you are monitoring litigation exposure

• Patent value concentrates in:
  • manufacturing process and presentation-specific claims
  • narrow method-of-use claims that are hard to design around without changing regimen

Key Takeaways

• Etanercept’s clinical development emphasis is shifting toward label refinement, switching strategies, and safety surveillance, not originator-scale breakthrough trials.
• The commercial outlook is dominated by biosimilar substitution, causing ongoing net-price erosion and originator share decline.
• Residual IP protection exists but is fragmented, with residual risks more likely tied to formulation/presentation and manufacturing process claims than to broad method-of-use barriers.
• Market growth through 2035 is more likely to come from continuity in the TNF segment and incremental uptake patterns than from major new indications.

FAQs

1. What are the most common endpoints used in current etanercept trials (RA/PsA/AS)?
   Disease activity scores (e.g., ACR response metrics in RA, PsA/AS activity indices), remission thresholds, and persistence/safety endpoints.

2. Do etanercept biosimilars compete only on price, or do they show clinical differentiation?
   Clinical differentiation is limited by comparability standards; real-world differentiation often comes from switching/persistence and procurement-driven adoption.

3. How do infection-risk and vaccination response studies affect etanercept prescribing?
   They influence monitoring protocols, adherence, and payer restrictions in higher-risk populations.

4. What presentation formats matter most for etanercept commercial uptake?
   Prefilled syringe and autoinjector convenience drive adherence; tender rules can favor specific SKUs.

5. Where can patent value still exist for mature etanercept products?
   Narrow formulation, container closure, device mechanics, and manufacturing process claims, plus any method-of-use claims still active and not easily designed around.

References

1. FDA. “Biosimilars.” US Food and Drug Administration.
2. FDA. “Approval Pathways: Biosimilar (BLA).” US Food and Drug Administration.
3. EMA. “Guideline on similar biological medicinal products.” European Medicines Agency.
4. GlobalData. Therapeutic area reports for TNF inhibitors and biosimilars (industry market research, accessed via institutional coverage).
5. IQVIA. Biologics and biosimilar market access and forecasting reports (industry market research, accessed via institutional coverage).